Author: Tyler Teske
Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don’t work, but because needles, cold chains, and $1,000-per-month pricing don’t scale. Fifty oral small-molecule programs are now racing to close that gap. Efficacy is converging. Deal flow is public. The question that will determine which become twenty-year franchises and which become commodities is the one most investors can’t answer: how deep is the IP protecting each molecule? We reviewed over 1,200 patent documents across 26 programs to find out.
HIGHLIGHTS
- The first oral small-molecule GLP-1 is days from approval. Orforglipron’s FDA decision date is April 10, 2026. Eli Lilly has built $1.5 billion in pre-launch inventory and priced the drug at $149–399/month.
- This is not one drug. It’s a drug class. Fifty oral small-molecule GLP-1 programs are in development worldwide, including programs from Novo Nordisk, Pfizer, Gilead, and Roche. Most investors can’t name more than one.
- Four scientific breakthroughs converged to make this possible. Structural biology, biased signaling, computational chemistry, and oral bioavailability engineering each independently matured between 2012 and 2022. Together, they unlocked a drug class the field had spent thirty years failing to build.
- Oral small molecules don’t compete with injectables. They expand the market. Current GLP-1 penetration is ~2% of the eligible US population. Oral pills with no fasting requirement and $5–15/month manufacturing cost unlock the other 98%.
- Efficacy is converging. The differentiator is underneath. Multiple programs deliver 12–16% weight loss. When clinical results look similar, the competitive moat is the patent architecture, and it varies enormously across programs at the same development stage.
- More than $47 billion has been committed since 2023. Every major pharma company is building an oral GLP-1 position. Roughly 80% of clinical-stage programs remain unpartnered.
- Patent depth varies wildly, and most investors can’t see it. We reviewed over 1,200 patent documents across 26 programs. Two have franchise-level IP architecture. Several Phase 3 programs have patent portfolios thinner than Phase 1 competitors.
- The next twelve months will reshape the landscape. FDA decisions, Phase 3 readouts, Medicare coverage expansion, and semaglutide’s approaching patent cliff are all converging.
1.0 A Quick Orientation
This report is written for investors, business development professionals, and anyone evaluating the oral GLP-1 landscape. If you are already fluent in clinical development, receptor pharmacology, and basic IP, skip ahead. If not, this section gives you just enough to follow the rest.
- Clinical development stages. Drug development runs through a set of phases. Phase 1 tests safety, tolerability, and basic pharmacokinetics in a small group (typically 20-100 people). Phase 2 tests efficacy and side effects in a larger group (100-500), often with multiple doses to find the optimal dose. Phase 3 is the pivotal trial: large, confirmatory studies (1,000-10,000+ patients) designed to prove the drug works well enough, and safely enough, for approval. NDA/BLA (New Drug Application / Biologics License Application) is the package filed to the FDA requesting approval. The FDA typically has a 10-month review clock, ending at a target decision date called the PDUFA date.
- Placebo-adjusted body weight loss (BWL). The main efficacy metric in obesity trials. If patients on drug lose 16% of body weight and patients on placebo lose 2%, the placebo-adjusted BWL is 14%. Cross-trial comparisons almost always use placebo-adjusted BWL, but they remain imprecise because trials differ in duration, patient mix, and dosing.
- GLP-1 receptor agonist. A drug that activates the GLP-1 receptor (GLP-1R), mimicking the natural GLP-1 hormone. Activation triggers insulin release, suppresses appetite, and slows gastric emptying, driving weight loss and glycemic control. Injectable peptide agonists (semaglutide, tirzepatide) already power a multi-tens-of-billions market. Oral small-molecule agonists are the focus of this report.
- Biased agonist / biased signaling. GLP-1R signals through at least two major pathways: G-protein-mediated cyclic AMP (cAMP) and beta-arrestin. cAMP drives most of the therapeutic effect (glucose control, appetite, weight loss); beta-arrestin is tied to receptor internalization, desensitization, and gastrointestinal side effects. A biased agonist preferentially activates one pathway (e.g., cAMP) over another (beta-arrestin), aiming to preserve efficacy while improving tolerability. Several leading oral programs are explicitly designed as cAMP-biased agonists.
- Covalent binder. Most drugs bind reversibly to their receptor. A covalent binder forms an irreversible chemical bond, often via a “warhead” such as an acrylamide group. Orforglipron is the only confirmed covalent oral GLP-1R agonist in development: a pyrazolopyridine that forms a covalent bond with GLP-1R, which helps drive potency and duration but raises specific safety and IP questions.
- Scaffold and benzimidazole. The scaffold is the core chemical backbone of a small molecule; it determines the overall shape, many pharmacokinetic properties, and often the patent family. Multiple oral GLP-1 programs use a benzimidazole scaffold (including Pfizer’s danuglipron and several Phase 2-3 assets). Benzimidazoles can carry CYP2C19-linked metabolic liabilities and overlapping prior art, which matters for both safety and freedom-to-operate.
- Composition of matter (CoM) patent. A patent that covers the specific chemical structure of a drug molecule. This is typically the most valuable patent a drug has, because it protects the molecule itself regardless of formulation or indication. When the core CoM patent expires, true generic competition usually begins.
- Patent family and Markush claim. A patent family is a group of related applications and grants that all descend from the same priority filing and cover variations on a shared invention (for example, a scaffold and its close analogs). Portfolio “depth” in this report is measured in families, not just document counts. A Markush claim is a broad claim format that covers a whole class (genus) of related molecules built around a common core, instead of a single structure. For small-molecule GLP-1, Markush scope is the difference between owning one asset and owning a chemical neighborhood.
- Freedom to operate (FTO). The practical question of whether a company can develop and sell its drug without infringing someone else’s patents. A program can have its own CoM patent and still face FTO risk if it sits inside another company’s broader Markush genus or method-of-use claims. Several benzimidazole programs sit close to Pfizer’s prior art; some later-stage assets have thinner portfolios than earlier-stage competitors.
- Deal economics (upfront, milestones, total value). When we describe a “$2B” or “$6B” deal, that is almost always a total potential number: upfront cash paid at signing, plus development and sales-based milestones that are only paid if specific events occur (trial success, approvals, sales thresholds). The true committed capital at signing is the upfront; for HRS-7535 and similar deals, that upfront is a small fraction of the headline figure.
With these building blocks in place, we can talk about what actually matters: which oral small-molecule GLP-1 programs exist, how they work, what their IP looks like, and who is likely to own this drug class.
2.0 April 10, 2026
On April 10, the FDA will decide whether to approve orforglipron, the first oral small-molecule GLP-1 receptor agonist for chronic weight management. If approved, it will be the first time a patient can treat obesity with a once-daily pill that works as well as the injections that built a $71 billion market.
Eli Lilly is not waiting for the answer. The company has built $1.5 billion in pre-launch inventory, nearly triple the $550 million stockpiled a year earlier. Pricing is set: $149 per month at the starter dose, $399 at maintenance, through LillyDirect. No prior authorization. No fasting requirement. No refrigeration.
The clinical case is already made. In the ATTAIN-1 trial, orforglipron delivered 14.7% placebo-adjusted weight loss at 72 weeks in non-diabetic adults, comparable to the injectable GLP-1s that currently dominate the market. ATTAIN-MAINTAIN showed patients could switch from injectable GLP-1s to orforglipron and hold their weight loss within one kilogram over a year. ACHIEVE-3 demonstrated superiority over oral semaglutide in glycemic control.
The molecule itself is unlike anything else in development. Orforglipron is a pyrazolopyridine: a compact chemical compound that forms an irreversible covalent bond with the GLP-1 receptor via an acrylamide warhead. It is not a shrunken peptide. It is not a reformulated injectable. It is a new kind of drug, designed from the receptor structure outward, manufactured via chemical synthesis, and delivered as a standard oral tablet.
This approval, if it comes, will validate a concept that the pharmaceutical industry spent thirty years failing to achieve: a small molecule that fully activates a receptor previously thought to require a large peptide. That’s a scientific inflection point.
But orforglipron is not the story. It’s the beginning of one.
3.0 Fifty Programs and Counting
Most investors can name one oral GLP-1 program. Here’s why that’s a problem.
Most investors tracking GLP-1s can name orforglipron. Some can name two or three competitors. Almost nobody knows what’s actually behind it.
There are fifty oral small-molecule GLP-1 receptor agonist programs in development worldwide, spanning every stage from NDA filing through preclinical discovery. Thirty are in clinical development. The rest are coming.
The pipeline breaks down like this:
Oral Small-Molecule GLP-1 Pipeline by Development Stage
| Stage | Programs | Notable Entrants |
| NDA / BLA | 1 | Orforglipron (Eli Lilly / Chugai) |
| Phase 3 | 4 | HRS-7535 (Hengrui / Kailera), VCT-220 (Corxel), Conveglipron (Huadong), MDR-001 (MindRank) |
| Phase 2 / 2–3 | 10 | Aleniglipron (Structure), ECC-5004 (AZ), CT-996 (Roche), RGT-075 (Regor), ASC30 (Ascletis), and 5 others |
| Phase 1 | 13 | GS-4571 (Gilead), CT-966 (Roche), NNC-92041706 (Novo Nordisk), TERN-601 (Terns), BMF-650 (Biomea), and 8 others |
| IND | 2 | WBD-2302 (Wayne Biotech), BEBT-808 (BeBetter Med) |
| Preclinical / Discovery | 20 | Lotiglipron (Pfizer), GSBR-2nd Gen (Structure), RP-2895 (Rivus), and 17 others |
The preclinical tier alone (20 programs) is larger than the entire clinical pipeline was two years ago.
Read that list again. Novo Nordisk, the company that built the injectable GLP-1 market with semaglutide, has a small-molecule program in Phase 1. Pfizer, which killed danuglipron in 2023 after hepatotoxicity-related tolerability failures, is back with a new discovery-stage compound. Gilead has a Phase 1 program with one of the largest patent portfolios in the entire landscape. Roche is running two programs simultaneously. Structure Therapeutics already has a second-generation compound in preclinical development behind aleniglipron.
These are not speculative biotech bets. When Novo Nordisk, Pfizer, Gilead, Roche, AstraZeneca, and Eli Lilly are all building oral small-molecule GLP-1 programs, this is not a niche. It’s the next standard of care.
The fourteen programs that have advanced to Phase 2 or beyond are the ones to watch closest:
The Programs That Matter Most
| Asset | Company | Phase | One-Liner |
| Orforglipron | Eli Lilly / Chugai | NDA | First-to-market. Covalent binder. 14.7% weight loss at 72 weeks. |
| HRS-7535 | Hengrui / Kailera | Phase 3 | ~$6B deal. Fused benzimidazole. Speed-to-market strategy. |
| VCT-220 (CX11) | Corxel / Vincentage | Phase 3 | China Phase 3, US Phase 2. 8.1% weight loss at 16 weeks. |
| Conveglipron | Huadong Medicine | Phase 3 | Limited public data. Self-funded. |
| MDR-001 | MindRank | Phase 3 | AI-designed. Beta-arrestin-selective. Lowest discontinuation rate in the field. |
| RGT-075 | Regor Therapeutics | Phase 2/3 | Self-funded. Moderate patent portfolio. |
| Aleniglipron | Structure Therapeutics | Phase 2 | Best-in-class efficacy (15.3%). Deepest unpartnered IP. Computational design. |
| ECC-5004 | Eccogene / AstraZeneca | Phase 2 | AZ’s $2B bet. Biased agonism. Full data at ADA June 2026. |
| CT-996 | Carmot / Roche | Phase 2 | Acquired via $2.7B Carmot deal. Benzimidazole scaffold. |
| ASC30 | Ascletis | Phase 2 | Tolerability standout. ~Half the vomiting rate of orforglipron. |
| HS-10501 | Hansoh Pharma | Phase 2 | Self-funded. Moderate-to-large patent portfolio. |
| SAL-0112 | Salubris Pharma | Phase 2 | Benzimidazole scaffold. Self-funded. |
| DA-302168S | Di’ao Pharma | Phase 2 | Limited disclosure. Self-funded. |
| Naperiglipron | Eli Lilly | Phase 2 | Lilly’s second oral GLP-1. Likely deprioritized behind orforglipron. |
Each of these programs represents a different bet: a different chemical scaffold, a different signaling profile, a different commercial strategy, a different patent position. Understanding what separates them requires understanding how this drug class became possible in the first place.
4.0 How Oral Small Molecules Became Possible
Thirty years of failure, then four breakthroughs converged in five years.
The transition from three decades of failure to 31 active clinical programs occurred in under five years. This wasn’t luck. It required the convergence of four enabling technologies (structural biology, biased signaling pharmacology, computational chemistry, and oral bioavailability engineering), each maturing between 2012 and 2022. Each alone was necessary but insufficient. Together, they unlocked what the field had considered pharmacologically intractable.
4.1 The Structural Problem
The GLP-1 receptor belongs to the Class B family of GPCRs, with a two-domain architecture: a large extracellular domain (ECD) serving as the initial recognition site, and a seven-transmembrane domain (7TMD) into which the peptide’s N-terminus inserts. Native GLP-1 (a 31-amino-acid peptide of ~3,300 Daltons) makes more than 20 simultaneous contact points across both domains.
Small molecules range from 300 to 700 Daltons. They access only the transmembrane pocket. This structural incompatibility was fatal throughout the 1990s and 2000s.
Screening campaigns at Novartis, GSK, Novo Nordisk, and Merck identified compounds that weakly activated GLP-1R but achieved only 20–40% of native GLP-1’s maximal efficacy. Without knowledge of the receptor’s three-dimensional binding pocket, medicinal chemists optimized through iterative trial-and-error. The industry consensus: small molecule GLP-1R agonism was a pharmacological dead end.
4.2 The Structural Biology Revolution (2012–2020)
Advances in cryo-electron microscopy and X-ray crystallography transformed the target from an unknown to a known entity. The timeline: inactive-state structure (Hollenstein et al., 2012); active-state structure with G-protein bound (Zhang et al., Nature, 2017); first small molecule agonist bound in the transmembrane pocket (Bueno et al., PNAS, 2020). Between 2021 and 2024, additional structures captured agonist conformations, biased signaling states, and allosteric binding modes.
This shifted drug discovery from empirical screening to structure-guided design. Medicinal chemists could now visualize the binding pocket at atomic resolution, identify critical amino acid residues, and distinguish how different binding modes produce divergent signaling outcomes.
The practical impact was dramatic. Virtual screening of libraries exceeding 100 million compounds yielded thousands of high-quality hits within weeks, a process that previously required years and produced only weak partial agonists. Lead optimization cycles compressed from 50–100 rounds of synthesis to 5–10 cycles. The hit-to-lead timeline shrank from three-to-five years to six-to-eighteen months.
Orforglipron exemplifies this. Eli Lilly, collaborating with Chugai, leveraged the 2020 small molecule-bound structure to design a compound that optimizes contacts with His7, Glu9, and Tyr148. This achieved full agonist activity while occupying a fraction of the surface engaged by native GLP-1, a level of efficacy that had eluded the prior generation of empirically screened compounds entirely.
4.3 Biased Signaling
GLP-1R signals through two principal pathways: G protein-mediated cyclic AMP (cAMP) production, which drives glucose-dependent insulin secretion, appetite suppression, and weight loss; and beta-arrestin recruitment, which promotes receptor internalization, desensitization, and gastrointestinal adverse events that limit tolerability.
Native GLP-1 and its peptide analogs (semaglutide, tirzepatide) activate both pathways in roughly equal proportion. They are “balanced” agonists. Small molecules could be engineered differently.
The critical insight, emerging between 2015 and 2020, was that small molecules could stabilize specific receptor conformations that preferentially couple to G proteins while minimizing beta-arrestin recruitment. This biased agonism offered a theoretical pathway to drugs that preserved therapeutic signal while reducing desensitization and tolerability burden.
Peptides cannot replicate this. Peptides engage the extracellular domain in a manner that inherently activates both downstream cascades. Small molecules binding within the transmembrane domain can selectively stabilize pathway-specific conformations. This is a structural advantage unique to the small molecule binding mode.
The operative question shifted from “can a small molecule activate GLP-1R?” to “can a small molecule activate GLP-1R’s therapeutic pathway selectively?” The latter is substantially more tractable. Clinical evidence validates this approach: aleniglipron (15.3% weight loss, the most efficacious oral asset in the current pipeline) and ASC30 (approximately half the vomiting rate of orforglipron, the most tolerable) are both cAMP-biased agonists.
4.4 Computational Chemistry at Scale (2016–Present)
Structure-based drug design existed before the GLP-1R structures were solved. But atomic-resolution receptor structures combined with modern computational tools created a fundamentally different capability, one that compressed timelines and expanded the chemical space amenable to systematic exploration.
Molecular docking engines such as Schrödinger’s Glide evaluate binding poses across vast libraries. Free energy perturbation (FEP+) methods predict binding affinity changes from structural modifications with increasing accuracy. ADME prediction tools such as QikProp filter for oral bioavailability, hepatic metabolism liability, and off-target binding risk before synthesis. AlphaFold and emerging machine learning models for ADMET prediction accelerated cycles further.
This workflow is fundamentally distinct from traditional medicinal chemistry. Virtual screening evaluates tens to hundreds of millions of compounds in silico. Physics-based modeling predicts receptor-ligand dynamics. Multi-parameter optimization happens computationally rather than at the bench.
Structure Therapeutics illustrates this most directly. Co-founded with Schrödinger in 2016, the company employed computational chemistry as the foundation of its discovery platform from inception. Its lead asset, aleniglipron, was identified and optimized using structure-based design, advancing from discovery to Phase 2b completion in under five years, roughly half the industry average. The broader pipeline spanning amylin, GIP, glucagon, and apelin receptor agonists reflects a platform-driven approach to GPCR discovery that would have been infeasible without computational scale.
4.5 Oral Bioavailability Engineering
GLP-1R’s large transmembrane binding pocket demands molecules in the 700–1,000 Dalton range with polar functional groups necessary for receptor engagement. Conventional oral drugs conform to Lipinski’s Rule of Five: MW below 500 Daltons, limited lipophilicity, restricted hydrogen bonding. The field resolved this conflict through complementary medicinal chemistry strategies.
Scaffold rigidity, employing constrained ring systems that maximize potency per heavy atom, enabled compounds such as MDR-001 (549 Daltons, among the smallest known GLP-1R agonists) to achieve meaningful receptor activation within conventional molecular weight. Metabolic stability engineering, incorporating fluorine atoms to block CYP450 oxidation and employing heteroaromatic cores resistant to hepatic degradation, extended half-lives into the 10–24 hour range for once-daily dosing. Permeability optimization through intramolecular hydrogen bonding reduced effective polarity during membrane transit, enabling passive absorption without absorption enhancers.
This bioavailability profile represents a qualitative advance over the oral peptide approach. Oral semaglutide (Rybelsus) achieves approximately 1% bioavailability through SNAC-mediated enhancement, requiring 14–50 mg per dose with strict fasting conditions. Oral small molecules achieve estimated bioavailabilities of 20–50% through standard pharmaceutical mechanisms: no absorption enhancer, no fasting requirement, no food or water restrictions. This is not an incremental pharmacokinetic improvement; it is a fundamental change in the delivery profile that underpins platform-level advantages.
4.6 Convergence
No single breakthrough was sufficient. The structural biology revolution revealed the target architecture but did not resolve the challenge of full agonism. Biased signaling provided a design principle but required high-resolution structural data. Computational chemistry could screen billions of compounds but needed a defined target and clear pharmacological objectives. Oral bioavailability engineering could optimize absorption only after potent, selective, and appropriately biased compounds had been identified.
The timeline of convergence is instructive. First GLP-1R crystal structure: 2012. Active-state structure with G-protein: 2017. Small molecule-bound structure: 2020. Biased signaling as a design principle: 2018–2020. Computational platforms at requisite scale: 2016–2018. The first wave of clinical candidates (orforglipron, IND 2021; aleniglipron, first-in-human 2021; ECC-5004, IND 2022) entered development precisely when all four technologies matured simultaneously.
Pfizer’s danuglipron is instructive as a case of partial convergence. Entering Phase 3 in 2020, it was discontinued in 2023 due to hepatotoxicity. The program benefited from structural biology but employed a balanced (non-biased) signaling profile on a benzimidazole scaffold that proved hepatotoxic at therapeutic exposures. The pattern across the broader pipeline is consistent: assets that integrated all four enabling technologies are the assets that now lead the field. Those relying on only a subset are disproportionately represented among failed or stalled programs.
This convergence carries implications for competitive dynamics. The structural data underlying GLP-1R drug design is publicly available, but the expertise required to translate crystallographic coordinates into viable drug candidates is concentrated within a small number of specialized teams. Computational platforms demand significant hardware infrastructure and domain-specific training data. Most critically, the accumulated medicinal chemistry knowledge surrounding GLP-1R oral bioavailability (how to balance potency, selectivity, signaling bias, and absorption within a single molecular scaffold) represents years of proprietary optimization that cannot be readily transferred or replicated.
These four breakthroughs created the molecules. But what makes oral small molecules a platform (not just an alternative delivery format) is what they unlock.
5.0 What Oral Small Molecules Actually Unlock
Injectable GLP-1s built a $71 billion market by being the most effective obesity drugs ever created. Oral small molecules won’t replace them. They’ll do something bigger: unlock the 95% of the eligible population that injectables can’t reach.
5.1 Three Platforms, One Receptor
Every GLP-1 receptor agonist in development or on the market falls into one of three categories, distinguished not by what receptor they hit (they all activate GLP-1R), but by what they’re made of and how they get into the body.
Injectable peptides are engineered versions of the natural GLP-1 hormone, large biological molecules (~3,300–5,000 Daltons), manufactured via fermentation, stabilized with fatty acid chains, delivered by subcutaneous injection once weekly. Wegovy, Ozempic, Mounjaro, Zepbound. The efficacy ceiling is high (15–22.5% weight loss), but the format constrains who can access treatment.
Oral peptides are the same large molecules reformulated to survive the gut. Novo Nordisk’s oral semaglutide uses SNAC technology to shield the peptide from enzymatic degradation in the stomach. It works: the Wegovy pill matched injectable efficacy at 16.6% weight loss in OASIS-4. But less than 1% of the drug is absorbed. A daily 25mg pill consumes more API than ten weekly 2.4mg injections. Patients must fast for 30 minutes with no more than 4 ounces of water. The economics and patient burden create a ceiling on scale.
Oral small molecules are compact chemical compounds (300–700 Daltons), designed from scratch, manufactured via chemical synthesis. Standard pharmaceutical absorption yields 20–50% bioavailability. No fasting required. Room-temperature stable. No absorption enhancer needed.
The differences are not incremental. They are structural.
Three platforms serve the same receptor. Only one can scale to the full addressable market.
Platform Comparison
| Dimension | Injectable Peptide | Oral Peptide | Oral Small Molecule |
| Administration | Once-weekly SC injection | Once-daily pill; 30-min fast, ≤4 oz water | Once-daily pill; no restrictions |
| Bioavailability | ~100% (SC) | <1% | 20–50% |
| Storage | Refrigerated (2–8°C) | Room temperature | Room temperature |
| Manufacturing | Biological fermentation; capacity-constrained | Same + 10–100x more API per patient | Chemical synthesis; standard pharma scale |
| Estimated COGS | $50–100/month | Very high (10x API consumption) | $5–15/month at scale |
| Combo Potential | Limited (co-formulation of biologics is complex) | Limited (SNAC interaction constraints) | High (standard fixed-dose combination) |
The cost line is the one that matters most. At $5–15 per month manufacturing cost, oral small molecules can be priced for primary care, for emerging markets, for maintenance therapy, segments that injectable pricing structurally excludes.
5.2 The 95% Gap
Current US penetration for GLP-1 pharmacotherapy is roughly 2% of the eligible population. Globally, closer to 1%. Of the 100 million Americans who could benefit from medical obesity treatment, fewer than 5 million are currently on a GLP-1.
The gap is not an efficacy problem. Injectable GLP-1s deliver 15–22% weight loss. The gap is structural: most patients will not self-inject, list prices exceed $1,000 per month, and the cold-chain logistics required for injectable biologics barely exist outside the US, Western Europe, and Japan.
Oral small molecules are the only platform that can close this gap. They create four distinct market layers:
- The first layer is maximum efficacy: injectable multi-agonists (tirzepatide, retatrutide) for patients who need 20%+ weight loss and are willing to inject. This market exists today. Oral small molecules don’t compete here.
- The second layer is primary care: oral small-molecule GLP-1s as first-line therapy prescribed by general practitioners. Twelve to sixteen percent weight loss with standard pill convenience. This is the market being created now, and it is potentially larger than the first.
- The third layer is maintenance and step-down: patients who achieve target weight on injectables and switch to oral pills for long-term maintenance. Lilly’s ATTAIN-MAINTAIN trial already validated this pathway: patients switching from injectable GLP-1s to orforglipron maintained weight loss within one kilogram over 52 weeks.
- The fourth layer is global and emerging markets: Sub-Saharan Africa, Southeast Asia, Latin America. The only format that can realistically reach populations without cold-chain infrastructure or injectable-tier per-capita healthcare spending.
5.3 The Combination Frontier
There is one more unlock, and it may be the most consequential. Oral small molecules enable fixed-dose combinations that injectables cannot easily achieve.
The next wave of competitive differentiation in obesity pharmacotherapy is multi-target: GLP-1 paired with amylin analogs for additive weight loss, glucagon receptor agonists for hepatic fat reduction, or SGLT2 inhibitors for cardiovascular benefit. Combining two injectable biologics requires co-formulation of large, complex molecules with different stability requirements. Combining two oral small molecules is standard pharmaceutical development, the same process used to create every fixed-dose combination in the generic pharmacy aisle.
This isn’t theoretical. Aleniglipron’s patent portfolio already includes method-of-use claims covering co-administration with more than 20 anti-emetic compounds. Orforglipron’s portfolio includes combination claims with ActRII antibodies for muscle preservation. The programs that have both scaffold IP and combination IP will have the longest exclusivity windows and the broadest commercial potential.
A $100 billion market, a platform with structural advantages over every existing alternative, and fifty programs racing to capture it. Here’s who’s building what.
6.0 Who’s Building What
Fifty programs. Fourteen in Phase 2 or beyond. The landscape is moving faster than most models account for. The profiles of the leading programs vary wildly in mechanism, efficacy, deal structure, and patent position.
6.1 NDA / Approved
One program has reached NDA filing.
Orforglipron: Eli Lilly / Chugai
| Phase | Mechanism | Best BWL | Duration | Deal Status |
| NDA (PDUFA April 10, 2026) | Covalent GLP-1R agonist (pyrazolopyridine) | 14.7% | 72 weeks | Licensed from Chugai (2018) |
Orforglipron is the only covalent binder in the field, forming an irreversible bond with the GLP-1 receptor via an acrylamide warhead, a mechanism no other program shares. The pyrazolopyridine scaffold is structurally unrelated to every other clinical-stage compound. ATTAIN-1 delivered 14.7% weight loss at 72 weeks in non-diabetic adults. ATTAIN-MAINTAIN validated the injectable-to-oral switching pathway. ACHIEVE-3 demonstrated superiority over oral semaglutide in glycemic control.
Lilly has priced orforglipron at $149–399/month through LillyDirect and built $1.5 billion in pre-launch inventory. The patent portfolio spans 9 families and 202 documents, including a broad Markush genus that effectively claims the entire concept of covalent oral GLP-1 agonism. The covalent mechanism is both the scientific moat and the central IP question: does the mandatory acrylamide warhead requirement create a boundary competitors can’t cross, or a target they can design around?
6.2 Phase 3
Four programs have advanced to Phase 3, each with a distinct profile and competitive rationale.
Phase 3 Pipeline
| Asset | Company | Mechanism | Best BWL | Duration | Deal Status |
| HRS-7535 | Hengrui / Kailera | GLP-1R agonist (fused benzimidazole) | 6.87% | 26 weeks | ~$6B total (Kailera license) |
| VCT-220 (CX11) | Corxel / Vincentage | GLP-1R agonist (imidazole) | 8.1% PA | 16 weeks | $287M Series D1 raise |
| Conveglipron | Huadong Medicine | GLP-1R agonist | N/A | N/A | Self-funded |
| MDR-001 | MindRank | GLP-1R agonist (AI-designed heterocyclic) | ~3% (Ph1b) | 12 weeks | Self-funded |
The most notable entry is HRS-7535. Not for its clinical data (which is early), but for the deal economics. Kailera Therapeutics licensed HRS-7535 from Hengrui in a deal structured at up to $6 billion in total milestones, the largest oral GLP-1 transaction to date. The compound is a fused benzimidazole derivative incorporating a benzodioxane ring and a chiral oxetane; architecturally, it is the most complex benzimidazole variant in development. Efficacy at 26 weeks (6.87% weight loss at 180mg) is early and on a dose-escalation curve that hasn’t matured. The benzimidazole scaffold carries CYP2C19 metabolic liability. Patent filings show 8 families and 61 documents with genus-level claims on fused imidazole derivatives, but the first filing came 21 months after first-in-human dosing. This gap raises questions about priority dates and enforceability.
VCT-220 (CX11) is running Phase 3 in China with US Phase 2 topline expected in H1 2026. Corxel raised $287 million in January 2026 to fund global Phase 3. Efficacy at 16 weeks (8.1% placebo-adjusted) is competitive for the timeframe, but the patent portfolio (2 families, 33 documents) is among the thinnest at this development stage.
Conveglipron (Huadong Medicine) has limited public data and is self-funded. MDR-001 (MindRank) is the most pharmacologically differentiated program in Phase 3: the only confirmed beta-arrestin-2-selective GLP-1R agonist in clinical development. Phase 1b showed a 0.8% adverse-event discontinuation rate, an order of magnitude below most competitors. The MOBILE Phase 3 trial (750 participants) initiated in January 2026. If the tolerability advantage holds at scale, the beta-arrestin-selective mechanism could be a genuine differentiator for long-term adherence.
Of the four Phase 3 programs, only one (HRS-7535) has secured a major partnership. The other three are self-funded. This signals that the deal window in this space is still wide open.
6.3 Phase 2
Ten programs are in Phase 2 or Phase 2/3. This tier contains the widest range of competitive profiles: from the best efficacy data in the field to programs with almost no public disclosure.
Phase 2 Pipeline
| Asset | Company | Best BWL | Duration | Deal Status | Notable |
| Aleniglipron | Structure Therapeutics | 15.3% PA | 36 weeks | Unpartnered | Best-in-class efficacy. Computational design. Deepest unpartnered portfolio. |
| ECC-5004 | Eccogene / AstraZeneca | TBD (positive topline) |
N/A | ~$2B (AZ) | AZ’s oral GLP-1 bet. Full data ADA June 2026. |
| CT-996 | Carmot / Roche | TBD | N/A | $2.7B acquisition | Roche’s oral GLP-1 play. Benzimidazole scaffold. |
| RGT-075 | Regor Therapeutics | ~5% | 12 weeks | Self-funded | Phase 2/3. Moderate portfolio. |
| ASC30 | Ascletis | TBD | N/A | Self-funded | Tolerability standout. ~Half the vomiting rate of orforglipron. |
| HS-10501 | Hansoh Pharma | N/A | N/A | Self-funded | Large portfolio for Phase 2 (15 families, 53 docs). |
| SAL-0112 | Salubris Pharma | N/A | N/A | Self-funded | Benzimidazole scaffold. |
| Naperiglipron | Eli Lilly | TBD | N/A | Internal | Lilly’s second oral GLP-1. Likely deprioritized. |
| DA-302168S | Di’ao Pharma | N/A | N/A | Self-funded | Limited disclosure. |
| EXD391209 | Chengdu Aoda | N/A | N/A | Self-funded | Limited disclosure. |
Only two of the ten Phase 2 programs have secured partners. Both deals happened before the programs entered Phase 2.
Aleniglipron is the standout. Designed from the solved 3D structure of the GLP-1 receptor using Structure Therapeutics’ computational platform with Schrödinger, the compound uses a phosphonate pharmacophore rather than the standard carboxylic acid, structurally distinct from every other program in development. Phase 2b delivered 15.3% placebo-adjusted weight loss at 36 weeks (240mg), the highest reported figure for any oral small-molecule GLP-1 program. The dose-response curve had not plateaued. Zero documented drug-induced liver injury events. 2.7% adverse-event discontinuation rate. The phosphonate design avoids CYP2C19 metabolism entirely. Phase 3 initiation expected mid-2026. The patent portfolio (29 families, 182 documents) is the largest unpartnered portfolio in the space. With best-in-class data, no CYP2C19 liability, and Phase 3 imminent, the obvious question is: why is this still unpartnered, and how long can that last?
ECC-5004 (elecoglipron) is AstraZeneca’s oral GLP-1 bet, in-licensed from Eccogene for up to $2 billion ($185 million upfront) in November 2023. Both the VISTA (obesity) and SOLSTICE (T2DM) Phase 2 trials met primary endpoints in February 2026. Full data at ADA in June 2026 will determine whether the biased-agonism thesis translates to competitive efficacy numbers. The patent portfolio (2 families, 27 documents) is thin for an asset with a $2 billion deal structure.
CT-996 is Roche’s oral GLP-1 play, acquired through the $2.7 billion Carmot Therapeutics deal in December 2023. Currently in Phase 2. Benzimidazole scaffold with CYP2C19 liability and potential overlap with Pfizer’s prior art.
6.4 Phase 1
Thirteen programs are in Phase 1. Most have limited clinical data, but several have patent portfolios or company profiles that signal serious long-term intent.
Phase 1 Pipeline
| Asset | Company | Notable |
| GS-4571 | Gilead Sciences | 12 families, 165 docs; one of the largest portfolios in the entire landscape at Phase 1 |
| CT-966 | Carmot / Roche | 11 families, 84 docs; Roche’s second oral GLP-1 program |
| NNC-92041706 | Novo Nordisk | The injectable GLP-1 market leader is building a small-molecule program |
| TERN-601 | Terns Pharmaceuticals | US-based, obesity-focused |
| BMF-650 | Biomea Fusion | Covalent approach; one of only two in development alongside orforglipron |
| XW-014 | Sciwind Biosciences | 13 families, 48 docs |
| ID-110521156 | Ildong / Yunovia | 6 families, 66 docs |
| PF-06954522 | Nxera Pharma (ex-Pfizer) | Post-danuglipron; transferred from Pfizer |
| MLX-7006 | Biolexis Therapeutics | N/A |
| IBI-3032 | Innovent / Xinda | N/A |
| TQF3250 | Chia Tai Tianqing | N/A |
| WBD156 | Wayne Biotechnology | N/A |
| APH01727 | Apichope | N/A |
Two entries stand out. Gilead’s GS-4571 has a patent portfolio (12 families, 165 documents) that is deeper than several Phase 3 competitors. This signals that Gilead is building a long-term platform position, not just a single clinical candidate. And Novo Nordisk, the company that defined the injectable GLP-1 market, has a small-molecule program in Phase 1. When the market incumbent starts building in a competing format, the format shift is real.
Biomea Fusion’s BMF-650 is notable as the only other covalent GLP-1R agonist program besides orforglipron. If covalent binding proves to be a mechanistic advantage, BMF-650 will face freedom-to-operate questions relative to Lilly’s broad warhead-based genus claims.
6.5 Preclinical and Discovery
Approximately 20 additional programs are in preclinical or discovery stages. Notable entries include Structure Therapeutics’ second-generation GLP-1R agonist (GSBR-2nd Gen), Pfizer’s lotiglipron (a return to oral GLP-1 after danuglipron’s failure), and Rivus Pharmaceuticals’ RP-2895.
The depth of the preclinical pipeline reinforces the central point: this is not a one-drug story. It is a drug class with a decades-long competitive horizon. The programs entering preclinical today will be filing INDs in 2027–2028 and reaching Phase 2 data by 2030, long after the first wave of approvals has reshaped the market.
The clinical data across these fifty programs is converging. What separates them is underneath.
7.0 How Good Are They?
The headline efficacy numbers across the oral small-molecule GLP-1 landscape are converging, and that convergence is the most important competitive signal in the data.
Six programs have reported placebo-adjusted body weight loss data from controlled trials. The range spans from early Phase 1 results to mature Phase 2b and Phase 3 readouts, making direct cross-trial comparison imprecise. But the trend is clear.
Cross-Trial Efficacy Comparison
| Asset | Phase | Best BWL* | Duration | Population | Notes |
| Aleniglipron | Phase 2b | 15.3% | 36 weeks | Obesity | 240mg dose. Curve not plateaued. |
| Orforglipron | Phase 3 / NDA | 14.7% | 72 weeks | Obesity | ATTAIN-1. Most mature dataset. |
| Oral Semaglutide | Phase 3 | 16.6% | 68 weeks | Obesity | OASIS-4 (Wegovy pill, 25mg). Oral peptide, not small molecule. |
| VCT-220 (CX11) | Phase 2 | 8.1% | 16 weeks | Obesity | Early. Short duration. |
| HRS-7535 | Phase 2 | 6.87% | 26 weeks | Obesity | 180mg. Dose-escalation ongoing. |
| MDR-001 | Phase 1b | ~3% | 12 weeks | Obesity | Very early. Phase 3 initiated. |
* placebo-adjusted
Cross-trial comparisons carry important caveats: different durations, populations, dose-escalation schedules, and endpoint definitions make precise ranking unreliable. But the broad pattern is meaningful.
Aleniglipron’s 15.3% at 36 weeks on a curve that hadn’t plateaued suggests a ceiling above 15% with further dose optimization. Orforglipron’s 14.7% at 72 weeks is the most mature readout and the benchmark for regulatory approval. Oral semaglutide’s 16.6% at 68 weeks confirms that oral delivery can match injectable efficacy, but as an oral peptide with <1% bioavailability and strict fasting requirements, it occupies a different platform category.
The efficacy gap between oral small molecules and injectable multi-agonists is real. Tirzepatide delivers 22.5% weight loss (SURMOUNT-1). Retatrutide, a triple agonist, has shown up to 24.2% in Phase 2. But that gap is not about the delivery format. It’s about multi-agonism. A GLP-1-only molecule, whether injected or swallowed, has a pharmacological ceiling that dual and triple agonists exceed by targeting additional receptors (GIP, glucagon). The oral small-molecule programs currently in development are primarily GLP-1-only. The combination frontier, pairing oral GLP-1 with other targets in fixed-dose combinations, is where that gap closes.
7.1 Tolerability as the Differentiator
If efficacy is converging, tolerability may be what separates the winners.
GLP-1 receptor agonists share a class-wide side effect profile: nausea, vomiting, and diarrhea, driven at least in part by beta-arrestin signaling and receptor desensitization. The rates vary dramatically across programs. MDR-001, the only confirmed beta-arrestin-selective agonist, reported a 0.8% adverse-event discontinuation rate in Phase 1b, an order of magnitude below most competitors. Aleniglipron reported 2.7% discontinuation with zero DILI events. Both are cAMP-biased agonists, consistent with the hypothesis that biased signaling reduces tolerability burden.
The benzimidazole scaffold introduces an additional risk. Four programs (HRS-7535, CT-996, naperiglipron, and SAL-0112) share a benzimidazole core and with it CYP2C19 metabolic liability. Approximately 15–20% of East Asian populations are CYP2C19 poor metabolizers, creating elevated drug exposure and adverse event risk in a pharmacogenomically significant subgroup. Pfizer’s danuglipron, also benzimidazole-based, was discontinued in 2023 after hepatotoxicity-related tolerability failures. Whether the shared scaffold creates shared safety risk is an open question. But it creates shared regulatory scrutiny that every benzimidazole program must navigate.
Clinical data is visible to everyone. Deal flow is visible to everyone. The dimension that remains almost entirely opaque, and that will increasingly determine which programs build franchises and which become commodities, is underneath all of it.
8.0 Follow the Money
More than $47 billion in GLP-1-related deal value has been committed since 2023. The pace is accelerating: $8.4 billion in 2024, $20.2 billion in 2025, and billions more in the first weeks of 2026.
The math driving these deals is simple. A $100 billion-plus market is dominated by two companies: Novo Nordisk and Eli Lilly. Injectable GLP-1 leadership is locked. The oral small-molecule wave is the available entry point for everyone else, and every major pharmaceutical company is trying to get in.
Major GLP-1 Transactions (2023–2026)
| Deal | Value | Date | Type | Asset / Focus |
| AstraZeneca / CSPC | $18.5B | 2025 | Acquisition | Broader metabolic platform |
| Pfizer / Metsera | ~$10B | 2025 | Acquisition | Oral GLP-1 platform |
| Kailera / Hengrui | ~$6B total | May 2024 | License | HRS-7535 (oral GLP-1) |
| Novo Nordisk / Akero | $4.7B | 2025 | Acquisition | MASH / liver |
| Roche / Carmot | $2.7B | Dec 2023 | Acquisition | CT-996, CT-966 (oral GLP-1) |
| AstraZeneca / Eccogene | ~$2B ($185M up) | Nov 2023 | License | Elecoglipron (oral GLP-1) |
| Corxel | $287M | Jan 2026 | VC raise | CX11 global Phase 3 |
| Lilly / Chugai | Undisclosed | 2018 | License | Orforglipron (oral GLP-1) |
The largest transactions, AstraZeneca/CSPC at $18.5 billion and Pfizer/Metsera at ~$10 billion, reflect bets on the broader metabolic platform, not individual molecules. Kailera’s ~$6 billion HRS-7535 license is the most direct oral GLP-1 deal in the dataset, and it came before mature Phase 2 data was available. AstraZeneca paid $2 billion for elecoglipron on the strength of biased-agonism differentiation and a Phase 2 pipeline, with a patent portfolio of only 2 families.
8.1 What the Deals Reveal
Valuation in this space is multi-dimensional. Deal premiums are not driven by any single factor: not clinical phase, not efficacy data, not IP depth alone. Kailera paid $6 billion for clinical speed and a differentiated scaffold. AstraZeneca paid $2 billion for mechanism-of-action differentiation with thin IP. Roche paid $2.7 billion for two programs plus an entire chemistry platform. Each deal reflects a different thesis about where value accrues in the oral GLP-1 race.
Most assets are still unpartnered. Roughly 80% of clinical-stage programs have not been licensed or acquired, including aleniglipron, which has the best efficacy data and the deepest unpartnered patent portfolio in the space. For pharma BD teams, the window to acquire programs at reasonable valuations is closing as Phase 3 readouts approach and the FDA’s orforglipron decision validates the drug class.
The deal flow confirms that the space is real and accelerating. But the deals also surface a question that most analysis doesn’t address: if you’re paying $2–6 billion for an oral GLP-1 program, how do you evaluate the patent portfolio protecting that investment? What’s the difference between paying $6 billion for a franchise with genus-level Markush claims extending to 2048, and paying $6 billion for a clinical asset with a seven-year exclusivity window before generics arrive?
That question is the one most investors are least equipped to answer.
9.0 The Question Nobody’s Asking
Clinical data is public. Deal flow is public. Patent architecture is not.
Every analysis of the oral GLP-1 race covers the same dimensions: clinical phase, weight-loss percentage, deal size, commercial strategy. These are important. They are also visible to everyone.
The dimension that remains almost entirely opaque to public markets, and that will increasingly determine which programs build franchises and which become commodities, is the patent architecture protecting each molecule.
When multiple programs deliver comparable efficacy (12–16% weight loss), the competitive moat is no longer “my drug works better.” It becomes: my drug is protected by broad patent claims, layered secondary filings, and a defensive thicket that delays generic entry by a decade or more. That’s the difference between a twenty-year monopoly on a hundred-billion-dollar market and a seven-year sprint before generics erode pricing power.
9.1 What Patents Can Cover
A drug’s patent portfolio is not one thing. It’s four layers, each providing different protection and different barriers to generic competition.
Composition of matter covers what the molecule is: the chemical structure itself. The most valuable composition-of-matter patents use Markush claims: a generic structural formula with variable substituents that covers an entire class of related compounds, potentially thousands of molecules sharing a common core. Think of it as owning the neighborhood, not just one house. Narrower patents cover only the specific compound being developed; effective against exact copies but easy to design around by modifying a single functional group.
Formulation covers how the drug is delivered: salt forms, crystalline polymorphs, dosage formulations, bioavailability enhancements. These patents extend exclusivity beyond the base composition-of-matter term and create manufacturing barriers that generic companies must navigate.
Methods of use covers what the drug treats and how: approved indications, dosing regimens, titration protocols, combination therapies. Method-of-use patents can extend protection years past composition-of-matter expiry, particularly when they claim novel therapeutic combinations or administration protocols.
Methods of manufacturing covers how the drug is made: synthesis routes, purification processes, continuous-flow manufacturing. Less visible than composition-of-matter claims but capable of blocking generics from cost-effective production at scale.
Each layer independently extends exclusivity. A program with strong composition-of-matter patents plus formulation, method-of-use, and manufacturing layers can build staggered patent expirations spanning a decade or more beyond the base term. A program with a single narrow composition-of-matter patent and nothing else has a ticking clock.
9.2 What We Found
We reviewed the patent portfolios of 26 clinical-stage oral small-molecule GLP-1 programs: over 1,200 patent documents across more than 170 patent families. For three programs, we conducted full claim-level analysis, reading every patent filing and mapping the actual scope of protection. For the remainder, our analysis is based on portfolio metadata: family counts, document counts, filing dates, and filing titles.
Here is what we know.
Orforglipron has the most comprehensive patent architecture in the space. Nine families, 202 documents. The foundational composition-of-matter patent claims a broad Markush genus covering the pyrazolopyridine scaffold with a mandatory acrylamide warhead: every compound in the genus must carry it. This effectively patents the entire concept of covalent oral GLP-1 receptor agonism. The portfolio includes formulation patents covering spray-dried dispersion technology, process patents covering continuous stirred-tank reactor synthesis, and method-of-use patents covering titration protocols, switching from injectable GLP-1s, and combinations with ActRII antibodies for muscle preservation. Base composition-of-matter expiry is approximately 2036. With patent term extension and secondary layers, practical exclusivity extends to approximately 2047.
Aleniglipron has the deepest unpartnered portfolio. Twenty-nine families, 182 documents: the largest portfolio of any unpartnered program in the landscape. The foundational patent claims a broad Markush genus covering the polycyclic heteroaromatic core with a phosphonate pharmacophore, supported by more than 200 dependent claims specifying substitution patterns, ring-fusion topologies, and substituent classes. A second genus patent extends coverage to alternative pharmacophores: sulfonyl, sulfoximine, and amide variants, preemptively blocking the most obvious design-around strategies before competitors can execute them. Additional layers include a salt patent covering 14 polymorphic forms and method-of-use patents covering co-administration with more than 20 anti-emetic compounds. Staggered expiry spans 2040 to approximately 2048.
HRS-7535 presents the most complex IP picture in the landscape. Eight families, 61 documents. Updated patent data shows Hengrui has filed genus-level composition-of-matter claims covering fused imidazole derivatives, crystalline forms, and pharmaceutical salts, a broader portfolio than initial public filings suggested. However, the first patent filing came 21 months after first-in-human dosing. In patent law, public disclosure of a drug, including through clinical trial activity, can undermine the novelty of later filings. The 21-month gap between dosing the first patient and filing the first patent raises questions about whether these composition-of-matter claims can withstand prosecution challenges. The updated filings from 2025–2026 appear to address this gap with broader genus claims, but enforceability remains an open question. It’s a question worth approximately $6 billion, given the Kailera deal structure.
9.3 What We Don’t Know Yet
For most of the remaining 23 programs, we have portfolio size and filing metadata. We can see how many patent families each program has filed, when they were filed, and from the titles what they appear to cover. We cannot yet confirm the actual scope of the claims without reading the Markush structures and dependent claims in each filing.
What the metadata does show is striking. Patent portfolio depth varies enormously across similar development stages. Gilead’s GS-4571 has 12 families and 165 documents at Phase 1, deeper than several Phase 3 competitors. CX11 has 2 families and 33 documents at Phase 3. HDM1002 has 2 families and 13 documents at Phase 3. Elecoglipron has 2 families and 27 documents, with a $2 billion deal behind it.
Portfolio size alone doesn’t determine portfolio quality. However, the magnitude of these disparities signals that some programs are being valued primarily on clinical speed and deal momentum, while others are building defensible positions designed to last decades. Understanding which is which requires reading every claim, mapping every boundary, and stress-testing every portfolio.
That’s what our deep-dive reports will do.
10.0 The Next Twelve Months
The oral small-molecule GLP-1 landscape will look fundamentally different by early 2027. The next twelve months contain more catalysts than the previous three years combined.
Key Catalysts
| Timeline | Event | Why It Matters |
| April 2026 | Orforglipron FDA decision (PDUFA April 10) | First oral small-molecule GLP-1 approval. Sets the commercial benchmark. |
| H1 2026 | CX11 US Phase 2 topline | First US data for Corxel’s program. Regulatory inflection point. |
| June 2026 | Elecoglipron full Phase 2 data (ADA) | AstraZeneca’s $2B bet. Validates or challenges biased-agonism thesis. |
| Mid-2026 | Aleniglipron Phase 3 initiation | Best-in-class efficacy contender enters pivotal trials. Deal window may close. |
| July 2026 | Medicare obesity drug coverage expansion | Structural demand catalyst. Millions of newly eligible patients. |
| H2 2026 | MDR-001 MOBILE trial enrollment | Phase 3 pace signals whether tolerability advantage drives investigator interest. |
| 2026–2027 | HRS-7535 Phase 3 readout | Kailera’s $6B bet produces mature efficacy data. |
| 2027 | CT-996 Phase 2 readout (expected) | First read on whether the $2.7B Carmot acquisition yields a competitive asset. |
Every one of these events will reshape competitive positioning, deal activity, and investor attention in this space.
10.1 The Patent Cliff on the Horizon
The timeline for generic competition is already set. Semaglutide’s core composition-of-matter patent expires in December 2031. Tirzepatide’s expires in January 2036. When generic injectable GLP-1s arrive, the oral small-molecule programs with deep patent portfolios (genus claims extending to 2040 to 2048, layered secondary filings, staggered expirations) will be the only premium-priced options standing. The programs with narrow patents will face generic competition from both injectable biosimilars and small-molecule generics simultaneously.
10.2 What We’re Publishing Next
Report #2: Orforglipron, A Structural and Patent Stress Test. Eli Lilly’s 9-family, 202-document patent portfolio, analyzed claim by claim. We’ll map the Markush genus boundaries, test whether the mandatory acrylamide warhead creates an unbreachable moat or a prosecutable vulnerability, model the generic entry timeline under multiple scenarios, and assess freedom-to-operate implications for every covalent GLP-1R program in development.
After that: deep-dive reports on every Phase 2+ program in the landscape, evaluating patent portfolios against the standards that determine long-term franchise value.
The clinical data tells you which drugs work. The deal flow tells you where the money is going. We’re going to tell you which programs can defend their position, and which ones are renting their market share.
PV Pulse is published by PatentVest. For questions, licensing inquiries, or to discuss IP strategy for your portfolio, contact: [email protected].